You are here

Article Text

Article menu
Download PDFPDF
Therapeutics
Valacyclovir reduced genital herpes transmission in couples discordant for herpes simplex virus type 2 infection

https://doi.org/10.1136/ebm.9.5.146

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Corey L, Wald A, Patel R, et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med 2004;350:11–20.
    OpenUrlCrossRefPubMedWeb of Science

    
 
 Q In heterosexual couples who are serologically discordant for herpes simplex virus type 2 (HSV-2) infection, does once daily valacyclovir reduce the sexual transmission of genital herpes?

    Clinical impact ratings GP/FP/Primary care ★★★★★★☆ Infectious diseases ★★★★★☆☆

    METHODS

    Embedded ImageDesign:

    randomised placebo controlled trial.

    Embedded ImageAllocation:

    concealed.*

    Embedded ImageBlinding:

    blinded {participants, healthcare providers, data collectors, data analysts, and outcome assessors}†.*

    Embedded ImageFollow up period:

    8 months.

    Embedded ImageSetting:

    96 sites in the US, Canada, Europe, Latin America, and Australia.

    Embedded ImageParticipants:

    1498 couples ⩾18 years who were immunocompetent, heterosexual, monogamous, in good health, and using effective contraception. One (source) partner had clinically symptomatic genital HSV-2 infection, presence of recurrent genital herpes with <10 episodes/year, and non-use of any daily antiviral therapy. The other (susceptible) partner had HSV-2 seronegativity on Western …

    View Full Text

    Footnotes

    • ↵* See glossary.

    • ↵† Information provided by author.

    • For correspondence: Dr L Corey, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. lcoreyu.washington.edu

    • Sources of funding: GlaxoSmithKline Research and National Institutes of Health.